Partek Expands Global Operations
News Mar 29, 2011
The company now has personnel throughout Europe — United Kingdom, France, Germany, Spain and Croatia — and a wholly owned subsidiary in Singapore servicing Asia, Australia and New Zealand.
Complementing a strong US-based support team, Partek’s regional managers have extensive expertise in biology and statistics, and are strategically positioned to assist scientists around the globe with analyzing their microarray and next-generation sequencing (NGS) studies. In addition to its direct operations, Partek also maintains partnerships with local distributors in more than a dozen countries, and worldwide reseller agreements with genomics device manufacturers Life Technologies Corporation and Affymetrix, Inc.
“It’s an exciting time at Partek, as rapid advances in genomics technology are fueling worldwide demand for software that simplifies and accelerates the data analysis process,” said Tom Downey, President of Partek Incorporated. “We are continuing to see a 95+ percent renewal rate among current Partek Genomics Suite licensees, and significant growth in new markets where NGS adoption is increasing. Our dedication to training and individual user-level support helps further differentiate our offering, and it is opening new doors to researchers seeking both the best-quality software and a knowledgeable team that stands behind it.”
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE